Efficacy and Safety of Banhahubak-Tang for Depression Treatment: Study Protocol for a Randomized, Waitlist-Controlled Trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Depression is a highly prevalent disease, and the market for antidepressant drugs continues to grow at a steady rate. Although current antidepressants are reported to be effective, because of their low remission rate and side effects, new antidepressants are needed. The use of Banhahubaktang (BHT) to treat the symptoms of depression is supported by experimental evidence. The proposed study will evaluate the efficacy and safety of BHT in treating depression. Methods: A randomized, waitlist-controlled, parallel clinical trial will be conducted to assess the efficacy of BHT in depression. A total of 84 participants with depression will be randomized into the intervention group or waitlist-control group at a 1:1 ratio. Patients in the intervention group will be administered BHT three times a day for four weeks and followed up for four more weeks after therapy completion. Patients in the waitlist-control group will undergo the same intervention and follow-up after a four-week waiting period. The primary outcome is change in the Korean version of the Hamilton Depression Rating Scale (K-HDRS) scores for major depressive disorders after four weeks. The secondary outcomes include scores on the K-HDRS, Korean Symptom Check List 95 (KSCL-95), Insomnia Severity Index (ISI), State-Trait Anxiety Inventory-Korean version (STAI-K), State-Trait Anger Expression Inventory-Korean version (STAXI-K), and the Instrument on Pattern Identifications for Depression and EuroQol-5 Dimension (EQ-5D). Conclusions: This trial will provide high-quality clinical evidence of the efficacy and safety of BHT in the management of depression.
Abstract
Objectives: Depression is a highly prevalent disease, and the market for antidepressant drugs continues to grow at a steady rate. Although current antidepressants are reported to be effective, because of their low remission rate and side effects, new antidepressants are needed. The use of Banhahubaktang (BHT) to treat the symptoms of depression is supported by experimental evidence. The proposed study will evaluate the efficacy and safety of BHT in treating depression. Methods: A randomized, waitlist-controlled, parallel clinical trial will be conducted to assess the efficacy of BHT in depression. A total of 84 participants with depression will be randomized into the intervention group or waitlist-control group at a 1:1 ratio. Patients in the intervention group will be administered BHT three times a day for four weeks and followed up for four more weeks after therapy completion. Patients in the waitlist-control group will undergo the same intervention and follow-up after a four-week waiting period. The primary outcome is change in the Korean version of the Hamilton Depression Rating Scale (K-HDRS) scores for major depressive disorders after four weeks. The secondary outcomes include scores on the K-HDRS, Korean Symptom Check List 95 (KSCL-95), Insomnia Severity Index (ISI), State-Trait Anxiety Inventory-Korean version (STAI-K), State-Trait Anger Expression Inventory-Korean version (STAXI-K), and the Instrument on Pattern Identifications for Depression and EuroQol-5 Dimension (EQ-5D). Conclusions: This trial will provide high-quality clinical evidence of the efficacy and safety of BHT in the management of depression.
참고문헌 (25)
- Kessler RC, "The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)", Jama, 289(23), pp.3095~3105 (2003)
- Wells KB, "The functioning and well-being of depressed patients : results from the Medical Outcomes Study", Jama, 262(7), pp.914~919 (1989)
- The global burden of disease:a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020: summary, "Murray CJ", World Health Organization, ~ (1990)
- EdinoffAN, "Selective serotonin reuptake inhibitors and adverse effects : a narrative review", Neurology International, 13(3), pp.387~401 (2021)
- Ulrich S, "Efficacy and adverse effects of tranylcypromine and tricyclic antidepressants in the treatment of depression : a systematic review and comprehensive meta-analysis", Journal of Clinical Psychopharmacology, 40(1), pp.63~74 (2020)
- Lo C, "Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications", Clin Transl Sci, 13(5), pp.861~870 (2020)
- Ali AM, "So, antidepressant drugs have serious adverse effects, but what are the alternatives?", Nov Appro Drug Des Dev, 4(3), pp.555~636 (2018)
- Jia KK, "Banxia-houpu decoction restores glucose intolerance in CUMS rats through improvement of insulin signaling and suppression of NLRP3 inflammasome activation in liver and brain", Journal of Ethnopharmacology, 209, pp.219~229 (2017)
- Lu HZ, "Effects of Banxia Houpu decoction on brain-derived neurotrophic factor (BDNF) in chronic stress and depression model rats", Chinese Medicine Information, (4), pp.49~50 (2008)
- Chen ZY, "Identification of the significant pathways of Banxia Houpu decoction in the treatment of depression based on network pharmacology", Plos One, 15(9), pp.e0239843~ (2020)
- Liu LY, "Herbal medicine for hospitalized patients with severe depressive episode : a retrospective controlled study", Journal of Affective Disorders, 170, pp.71~77 (2015)
- Xiao L, "Randomized controlled trial of modified banxia houpo decoction in treating functional dyspepsia patients with psychological factors", Chinese Journal of Integrated Traditional and Western Medicine, 33(3), pp.298~302 (2013)
- 나병조, "중풍후우울증에 대한 반하후박탕의 유효성 및 적응증 평가", 대한한방내과학회지, 26(3), pp.563~574 (2005), 대한한방내과학회
- Nakajima-Ohyama KC, "Usefulness of hangekobokuto(Banxia-houpo-tang)to treat panic disorder in patients with bipolar disorder : a case report", Traditional & Kampo Medicine, 8(3), pp.238~241 (2021)
- "World medical association declaration of Helsinki - Seoul revision. Vol. 53", pp.739~742 (2010), Journal of the Korean medical Association
- 이중서, "한국판 Hamilton 우울증 평가 척도의 신뢰도, 타당도 연구", 신경정신의학, 44(4), pp.456~465 (2005), 대한신경정신의학회
- Brouwers P, "Handbook of clinical trials", pp.396~ (1991), CRC Press
- Beck AT, "Psychometric properties of the Beck Depression Inventory : twenty-five years of evaluation", Clinical Psychology review, 8(1), pp.77~100 (1988)
- Park MS, "A case study of meditation counseling for reducing anxiety disorder of middle-aged men suffering from panic disorder", Journal of Meditation based Psychological Counseling, 15, pp.11~20 (2016)
- Morin CM, "The Insomnia Severity Index : psychometric indicators to detect insomnia cases and evaluate treatment response", Sleep, 34(5), pp.601~608 (2011)
- Spielberger CD, "The state-trait anxiety inventory", Revista Interamericana de Psicologia, 1971, pp.5(3 & 4), 145~158
- Spielberger CD, "Individual differences, stress, and health psychology", pp.89~108 (1988), Springer
- 이은희, "우울증 변증도구 개발을 위한 기초연구", 동의신경정신과학회지, 24(4), pp.435~450 (2013), 대한한방신경정신과학회
- Group TE, "EuroQol-a new facility for the measurement of health-related quality of life", Health policy, 16(3), pp.199~208 (1990)
- Hao X, "A randomized, double-blind, placebo-controlled study of Danzhi Ningshen Capsules in the treatment of mild to moderate depression", Chinese Journal of New Medicine, 24(17), pp.1992~1995 (2015)